- AU$14.72m
- AU$13.05m
- AU$3.53m
- 13
- 14
- 74
- 27
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.08 | ||
| Price to Tang. Book | 6.08 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.13 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -202.71% | ||
| Return on Equity | -196.58% | ||
| Operating Margin | -139.19% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 3.59 | 3.85 | 3.99 | 2.76 | 3.53 | n/a | n/a | 11.17% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AdAlta Limited is an Australia-based clinical-stage drug discovery company. The Company is engaged in the development of therapeutic products from its i-body platform. The Company has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patient’s immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patient’s immune system to recognize and kill diseased cells such as cancer. It develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. It evaluates several CXCR4 i-bodies.
Directors
- Paul MacLeman CHM
- Timothy Oldham CEO
- Dallas Hartman COO
- Michael Foley CSO
- Kate Griffiths OTH
- Cameron Jones SEC
- Elizabeth McCall DRC
- James Williams DRC
- David Fuller NED
- Robert Peach NED (62)
- Rosalind Wilson NED
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 22nd, 2006
- Public Since
- August 22nd, 2016
- No. of Shareholders
- 1,415
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 525,804,077
- Address
- Unit 15 / 2 Park Drive, Bundoora, MELBOURNE, 3083
- Web
- https://adalta.com.au/
- Phone
- +61 394795159
- Auditors
- Dry Kirkness
Upcoming Events for 1AD
Similar to 1AD
Actinogen Medical
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
FAQ
What is the Adalta share price?
As of Today at 19:00 UTC, shares in Adalta are trading at AU$0.03. This share price information is delayed by 15 minutes.
How has the Adalta share price performed this year?
Shares in Adalta last closed at AU$0.03 and the price had moved by +7.69% over the past 365 days. In terms of relative price strength the Adalta share price has outperformed the ASX All Ordinaries Index by +3.01% over the past year.
What are the analyst and broker recommendations for Adalta?
The overall consensus recommendation for Adalta is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Adalta dividend yield?
Adalta does not currently pay a dividend.
Does Adalta pay a dividend?
Adalta does not currently pay a dividend.
When does Adalta next pay dividends?
Adalta does not currently pay a dividend.
How do I buy Adalta shares?
To buy shares in Adalta you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Adalta?
As of the previous close price of AU$0.03, shares in Adalta had a market capitalisation of AU$14.72m.
Where are Adalta shares listed?
Here are the trading details for Adalta:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: 1AD
What kind of share is Adalta?
Based on an overall assessment of its quality, value and momentum Adalta is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Adalta share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Adalta share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adalta. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +3.83%.
As of the last closing price of AU$0.03, shares in Adalta were trading +19.09% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Adalta PE Ratio?
The Adalta PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Adalta?
Adalta's management team is headed by:
- Paul MacLeman - CHM
- Timothy Oldham - CEO
- Dallas Hartman - COO
- Michael Foley - CSO
- Kate Griffiths - OTH
- Cameron Jones - SEC
- Elizabeth McCall - DRC
- James Williams - DRC
- David Fuller - NED
- Robert Peach - NED
- Rosalind Wilson - NED